On Friday, Nuvalent Inc (NUVL) stock saw a decline, ending the day at $99.1 which represents a decrease of $-1.95 or -1.93% from the prior close of $101.05. The stock opened at $101.76 and touched a ...

Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to ...

In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

On Thursday, Doximity Inc (DOCS) stock saw a modest uptick, ending the day at $42.53 which represents a slight increase of $0.66 or 1.58% from the prior close of $41.87. The stock opened at $42.24 and ...

Leerink Partners analyst Puneet Souda reiterated a Buy rating on Quanterix (QTRX – Research Report) today. The company’s shares ...

Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives.

Capstan Therapeutics to participate in Goldman Sachs Cell Therapy Day 2024 and Leerink Partners Biopharma Private Company Connect.

and are “too far out chronologically to be credible from a management team that we think has proven serially unable to project the performance of their business,” wrote Leerink Partners analyst Mani ...

Regeneron (REGN) stock was downgraded by Leerink after a court ruling that favored Amgen's (AMGN) plans to introduce a biosimilar for REGN's Eylea. Read more here.